Methenolone Enanthate 175mg/mL

Primobolan Depot 175 by Pharmaqo Labs is an injectable anabolic steroid containing 175mg of methenolone enanthate per milliliter, typically in a 10ml vial. Methenolone enanthate, a DHT-derived compound, was developed in the 1960s for medical use in treating anemia from bone marrow failure and muscle wasting conditions by promoting lean tissue growth and red blood cell production. In bodybuilding, it’s favored for its mild profile, aiding in lean muscle preservation, fat loss, enhanced strength, and nitrogen retention during cutting or recomp phases, with minimal water retention or estrogenic effects due to non-aromatization.

Usage and Dosage

• Typical Dosage: For men in performance enhancement, 175-800mg per week, often split into 1-2 injections (e.g., 400-600mg for intermediates); beginners start lower at 200-400mg weekly. Women use 50-100mg per week to minimize virilization risks. Medical dosing is typically 100-200mg every 1-2 weeks intramuscularly.
• Cycle Length: 8-12 weeks for optimal results, followed by PCT (e.g., Clomid or Nolvadex) starting 14-21 days post-last injection to restore testosterone levels, as it suppresses natural production despite its mild nature.
• Stacking: Often paired with testosterone (e.g., Enanthate) for balanced gains, or with Anavar/Winstrol for cutting; avoids harsh compounds to maintain low side effect profile. Professional medical supervision is critical, including bloodwork for hormone levels and organ function; non-medical use is illegal in many regions.

Potential Side Effects and Risks

Primobolan is among the milder steroids but still carries risks, especially with higher doses or prolonged use:

• Common Side Effects: Androgenic effects like acne, hair loss (in predisposed individuals), mild suppression of natural testosterone, and potential cholesterol imbalances (e.g., raised LDL).
• Serious Risks: Cardiovascular strain, interference with glucose/thyroid tests, virilization in women (e.g., voice deepening), and in animal studies, potential heart hypertrophy. Contraindicated in prostate/breast cancer, liver/kidney issues, or pregnancy; may resist neuromuscular blockers.
• Other Considerations: Low hepatotoxicity compared to orals, but stacking increases overall risks; monitor for low estrogen symptoms if combined with test